论文部分内容阅读
Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.Background.Darbepoetin alfa is a glycoprotein with a threefold longer terminal half-life than recombinant human erythropoietin (rHuEPO).We aimed to determine whether darbepoetin alfa is as effective and well tolerated as rHuEPO for treating renal anemia in dialysis patients when administered at a reduced dose frequency.